16th December 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Maiden Pharma's cough syrups are safe, WHO jumped to conclusion: DCGI

India’s drug authority has written a letter to WHO declaring that the samples of Maiden Pharma’s cough syrup allegedly causing the death of Gambian children were not found to be contaminated with diethylene glycol (DEG) and ethylene glycol (EG) upon testing by a technical committee of the Indian govt.

Bharat Serums and Vaccines set to acquire Firstline Pharma, Genomicks

Bharat Serums and Vaccine Limited stated that they have entered into a definitive agreement to acquire Firstline Pharmaceuticals and Genomicks, to increase its presence in the women’s health and reproductive sector in Malaysia.

Eli Lilly says 4 new launches will help drive its revenue cross $30B in year 2023

As reported by executives in an investor presentation, upcoming year Lilly has planned to submit regulatory applications for five products plus begin with six phase 3 trials and present data from six other phase 3 trials. All this will help the company earn more than $30 billion in sales next year.

AbbVie exits significant pharmaceutical industry lobbying groups

One of the most profitable drugmaking company of the world is exiting pharmaceutical industry’s two major lobbying organizations the upcoming year, immediately after Washington pledges to cut down on increased drug costs.

Thea Pharma announces the approval of IYUZEH™ by USFDA

Thea Pharma, Inc. has announced the approval of its NDA (New Drug Application) by the USFDA for its drug IYUZEH™ (latanoprost ophthalmic solution) 0.005% for indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Eli Lilly and EVA Pharma to facilitate affordable insulin access in Africa

According to reports, Lilly is going to sell its API (Active Pharmaceutical Ingredient) for insulin at a significantly low price to Eva Pharma and will also provide a pro-bono technology transfer to help EVA Pharma to formulate, fill and finish insulin vials and cartridges.

First patient dosed in Small Pharma's Drug Interaction study

The Biotech company, “Small Pharma” declared that the first patient was dosed on thursday for its Phase Ib drug interaction study that aims to assess the interaction between selective serotonin reuptake inhibitors (SSRIs) and the Company’s lead N, N-dimethyltryptamine (DMT) candidate.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?